Godavari Biorefineries Q4 FY26 Results: Total Income ₹570 Cr, PAT ₹52.9 Cr
Godavari Biorefineries reported Q4 FY26 results with Total Income at ₹570 crore and PAT at ₹52.9 crore. For FY26, Total Income reached ₹2000.2 crore and PAT was ₹3.5 crore. The company achieved its highest-ever cane crushing of 2.5 Mn tonnes in the 2025-26 season. Jivana revenues crossed ₹129 crore in FY26.
The results show a mixed performance with year-on-year declines in key metrics for the quarter, although full-year results improved. The company's commentary indicates ongoing industry challenges but also strategic initiatives for future growth, suggesting a moderate impact on investor sentiment.
The company reported a decline in Q4 FY26 PAT year-on-year due to industry headwinds, but showed resilience and growth in full-year PAT. The management commentary acknowledges challenges but highlights strategic focus and future growth opportunities.
Godavari Biorefineries Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a Total Income of ₹570.0 crore for Q4 FY26, a decrease of 3.2% compared to ₹588.8 crore in Q4 FY25. EBITDA stood at ₹92.1 crore, down 24.3% year-on-year, and Profit After Tax (PAT) was ₹52.9 crore, a decline of 26.5% from ₹71.9 crore in the same period last year.
For the full fiscal year FY26, Total Income was ₹2000.2 crore, an increase from ₹1886.9 crore in FY25. However, EBITDA for FY26 was ₹139.3 crore, up from ₹120.3 crore in FY25, while PAT for FY26 was ₹3.5 crore compared to a loss of ₹23.4 crore in FY25.
Commenting on the results, CMD Shri Samir Somaiya highlighted a challenging operating environment for the sugar and ethanol industry due to elevated cane and feedstock costs. Despite these headwinds, the company's integrated business model and operational discipline enabled a resilient performance. The sugar business saw improved operational performance with the highest-ever cane crushing of 2.5 million tonnes during the 2025-26 season. The Bio-based Chemicals segment contributed meaningfully, with ethyl acetate realizations remaining favorable, though geopolitical disruptions impacted margins. The company is focused on increasing the share of higher-margin specialty products and improving capacity utilization.
During the quarter, Godavari Biorefineries was granted a Japanese patent related to antiviral therapeutics. The consumer business, Jivana, saw revenues cross ₹129 crore in FY26, up from ₹108 crore in FY25. Looking ahead, the company plans to scale its bio-based chemicals and ethanol businesses through debottlenecking and capacity optimization, while expanding its high-value bio-based chemicals portfolio.
What to do with a filing like this
Godavari Biorefineries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Godavari Biorefineries Limited. Read the original for the full detail.